A Phase 2 interventional study of sorafenib tosylate and placebo in Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by Jonsson Comprehensive Cancer Center. Completed at 21 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Jonsson Comprehensive Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.
Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 36th largest by enrollment, is one of 8 that started in 2012, is one of 44 in phase 2, and was the 65th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–99
Zhejiang Haichang Biotech Co., Ltd. · Sites in China, Hong Kong
Ages 18+
Assiut University · Sites in Egypt
Ages 18–80
St. Jude Children's Research Hospital · Sites in United States
Ages up to 30
Humanity & Health Medical Group Limited · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 59 · Phase 3 17 · Phase 4 3
First in 2002; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 44 across the 104 interventional studies. Of the 71 that completed or were terminated, 24 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 104 have an industry lead sponsor. The 10 most frequent:
Jonsson Comprehensive Cancer Center is the lead sponsor of 398 studies on the registry; 66 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.
10 studies in Carcinoma, Hepatocellular by Jonsson Comprehensive Cancer Center: none open now, 2 under way, none of them phase 3. Of 6 finished, 2 (33%) have results posted.
Among the 10 studies in Carcinoma, Hepatocellular by Jonsson Comprehensive Cancer Center, this one has the largest enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 6th registered.
Jonsson Comprehensive Cancer Center’s Carcinoma, Hepatocellular studies by the year they started, since 1998.
4 of the studies testing sorafenib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT06309485Zhejiang Haichang Biotech Co., Ltd.Phase 2 Study of WGI-0301 for Advanced HCC | 2026-12 |
| NCT05669339University of FloridaAD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | 2027-04 |
| NCT01840592Memorial Sloan Kettering Cancer CenterSorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, from their registry updates:
Among Jonsson Comprehensive Cancer Center’s 10 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation
PRIMARY OBJECTIVES:
I. Two-year recurrence free survival (RFS).
SECONDARY OBJECTIVES:
I. One-year recurrence free survival. II. Overall survival (OS). III. Safety. IV. Impact of drug-drug interactions (i.e. immunosuppression agents). V. Impact of biomarkers (alpha-fetoprotein [AFP], protein-induced by vitamin K absence or antagonist II [PIVKA II]).
VI. Effects of therapy on wound healing. VII. Impact of hepatitis C viral recurrence.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive sorafenib tosylate orally (PO) twice daily (BID).
ARM II: Patients receive placebo PO BID.
In both arms treatment continues for 24 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have hepatocellular carcinoma (HCC) with one of the following on explant: microvascular/macrovascular invasion, tumor outside of Milan criteria, poor tumor differentiation; patients with macrovascular invasion on explant pathology will be stratified
* Additionally, the following will be included
** Patients with elevated surrogate markers (AFP > 500 or PIVKA > 400) pre transplant and with proven HCC prior to orthotopic liver transplantation (OLT) or on explant
Patient has not received prior anti-angiogenic therapy, systemic targeted agents or systemic chemotherapy
* Prior surgical resection, chemoembolization or other local therapy prior to transplant is permitted
Exclusion Criteria:
Active or cardiac disease including:
Anticoagulation, as described below, is allowed:
Vitamin-K antagonists (e.g., warfarin)
** Low dose warfarin (1 mg orally, once daily) with PT- =\< 1.5 x is permitted; patients taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive sorafenib tosylate PO BID.
Drug: sorafenib tosylate · Other: laboratory biomarker analysis
Patients receive placebo PO BID.
Other: placebo · Other: laboratory biomarker analysis
Given PO
Also known as: BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN
Given PO
Also known as: PLCB
Correlative studies
Recurrence-free Survival at 2 Years
Recurrence-free Survival at 2 Years: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.
Time frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 2 years
Recurrence-free Survival at One Year
Recurrence-free Survival at One Year: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.
Time frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year
Overall Survival
The number of participants who were alive at the last available follow-up. Overall survival was defined as the time from randomization to death from any cause or the last date the participant was known to be alive.
Time frame: From randomization through the last available follow-up, approximately two years
Graft Failure Free Survival
Graft Failure Free Survival: The number of participants who remained alive without failure of the transplanted liver. Graft-failure-free survival was defined as the time from randomization to the first documented graft failure according to local clinical standards.
Time frame: From randomization through the end of study follow-up, approximately two years
Serum Alpha-fetoprotein (AFP) Correlation to Recurrence
Serum Alpha-fetoprotein (AFP) Correlation to Recurrence: Among participants who experienced hepatocellular carcinoma (HCC) recurrence, this outcome assessed whether serum alpha-fetoprotein (AFP), a blood biomarker used to monitor HCC, was associated with recurrence.
Time frame: From randomization through the end of study follow-up, approximately two years
Serum Alpha-fetoprotein (AFP) 24 Months
Serum Alpha-fetoprotein (AFP) 24 Months: Serum alpha-fetoprotein (AFP), a blood biomarker used to monitor hepatocellular carcinoma (HCC), was measured during follow-up. Results are reported as the median AFP level at 24 months.
Time frame: Assessed at two years
Adverse Events Assessed in Terms of Seriousness, Severity, and Relationship to the Study Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
See section four, Adverse events and serious adverse events
Time frame: Assessed from randomization through up to 30 days after last drug dose, approximately two years
Impact of Sorafenib-Tacrolimus Interactions
Median tacrolimus levels (ng/mL) measured at 24 months
Time frame: During the 24-month study treatment periodmeasured at 24 months
Wound Complications
Impact of therapy on wound healing
Time frame: During the 24-month study treatment period
Hepatitis C Viral Recurrence
data was insufficient to analyze the impact of Hepatitis C viral recurrence
Time frame: During the 24-month study treatment period
The study was opened with the first participant patient enrolled (at UCLA) 11/08/2012. The study was closed to accrual on 09/30/2017. High-risk hepatocellular carcinoma-liver transplant recipients were recruited to a phase II multicenter prospective randomized placebo-controlled trial (11-003311/NCT01624285) by 21 initially participating centers across the United States from July 2012 to September 2017.
| Milestone | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Started | 30 | 43 |
| Completed | 7 | 18 |
| Not completed | 23 | 25 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lack of efficacy | 2 | 4 |
| Withdrew: Lost to follow-up | 4 | 7 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 9 | 11 |
| Milestone | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Started | 30 | 43 |
| Completed | 14 | 22 |
| Not completed | 16 | 21 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lost to follow-up | 8 | 13 |
| Withdrew: Withdrawal by subject | 6 | 8 |
Recurrence-free Survival at 2 Years: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Recurrence-free Survival at 2 Years | 22 | 29 |
Recurrence-free Survival at One Year: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Recurrence-free Survival at One Year | 23 | 32 |
The number of participants who were alive at the last available follow-up. Overall survival was defined as the time from randomization to death from any cause or the last date the participant was known to be alive.
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Overall Survival | 22 | 34 |
Graft Failure Free Survival: The number of participants who remained alive without failure of the transplanted liver. Graft-failure-free survival was defined as the time from randomization to the first documented graft failure according to local clinical standards.
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Graft Failure Free Survival | 22 | 34 |
Serum Alpha-fetoprotein (AFP) Correlation to Recurrence: Among participants who experienced hepatocellular carcinoma (HCC) recurrence, this outcome assessed whether serum alpha-fetoprotein (AFP), a blood biomarker used to monitor HCC, was associated with recurrence.
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Serum Alpha-fetoprotein (AFP) Correlation to Recurrence | 1 | 2 |
Serum Alpha-fetoprotein (AFP) 24 Months: Serum alpha-fetoprotein (AFP), a blood biomarker used to monitor hepatocellular carcinoma (HCC), was measured during follow-up. Results are reported as the median AFP level at 24 months.
| ng/mL | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Serum Alpha-fetoprotein (AFP) 24 Months | 3.5 (2.3 to 4.8) | 4.0 (2.0 to 6.7) |
See section four, Adverse events and serious adverse events
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Adverse Events Assessed in Terms of Seriousness, Severity, and Relationship to the Study Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | 24 | 34 |
Median tacrolimus levels (ng/mL) measured at 24 months
| ng/mL | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Impact of Sorafenib-Tacrolimus Interactions | 5.5 (5 to 7.1) | 5.4 (3.5 to 7.075) |
Impact of therapy on wound healing
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Wound Complications | 1 | 0 |
data was insufficient to analyze the impact of Hepatitis C viral recurrence
| Participants | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| Hepatitis C Viral Recurrence | 0 | 1 |
Collected over up to 30 days after the last study drug dose.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (Sorafenib Tosylate) | 2/24 (8.3%) | 21/24 (87.5%) | 24/24 (100%) |
| Arm II (Placebo) | 0/34 (0%) | 31/34 (91.2%) | 34/34 (100%) |
| Event | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| NauseaGastrointestinal disorders | 0/24 | 3/34 |
| Liver transplant rejectionImmune system disorders | 2/24 | 0/34 |
| Metastatic hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/24 | 0/34 |
| Flank painGeneral disorders | 0/24 | 2/34 |
| Transaminases increasedInvestigations | 0/24 | 2/34 |
| Atrial fibrillationCardiac disorders | 1/24 | 0/34 |
| AscitesGastrointestinal disorders | 1/24 | 0/34 |
| ColitisGastrointestinal disorders | 1/24 | 0/34 |
| FeverGeneral disorders | 1/24 | 0/34 |
| JaundiceHepatobiliary disorders | 1/24 | 0/34 |
| Event | Arm I (Sorafenib Tosylate) | Arm II (Placebo) |
|---|---|---|
| DiarrheaGastrointestinal disorders | 16/24 | 7/34 |
| HypertensionVascular disorders | 10/24 | 8/34 |
| LeukopeniaBlood and lymphatic system disorders | 5/24 | 1/34 |
| NauseaGastrointestinal disorders | 5/24 | 4/34 |
| Peripheral edemaGeneral disorders | 5/24 | 2/34 |
| PruritusSkin and subcutaneous tissue disorders | 5/24 | 3/34 |
| RashSkin and subcutaneous tissue disorders | 5/24 | 1/34 |
| Abdominal painGastrointestinal disorders | 4/24 | 6/34 |
| FatigueGeneral disorders | 4/24 | 6/34 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/24 | 0/34 |
| Age, Continuous(years) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| Median | 63 (58 to 66) | 62 (59 to 67) | 62 (58 to 67) |
| Sex: Female, Male(Participants) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 19 | 32 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 19 | 30 | 49 |
| Race (NIH/OMB)(Participants) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 19 | 30 | 49 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Region of Enrollment(participants) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| United States | 24 | 34 | 58 |
| MELD (Model for End Stage-Liver Disease) Score(units on a scale) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| Median | 28 (24 to 31) | 28 (22 to 33) | 28 (22 to 33) |
| Indication for Liver Transplant (LT)(Participants) | Arm I (Sorafenib Tosylate) | Arm II (Placebo) | Total |
|---|---|---|---|
| Primary Hepatocellular Carcinoma (HCC) | 5 | 9 | 14 |
| End Stage Liver Disease + Primary Hepatocellular Carcinoma: ESLD+HCC | 19 | 25 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2012 to primary completion in Feb 2023, 123 months.
Results were first posted in Nov 2026, 3 years 9 months after primary completion.
Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's 123 months is above that.
Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
Start moved once since we started tracking on Sep 25, 2026: Jul 2012 → Nov 2012, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sorafenib
Jonsson Comprehensive Cancer Center →